Oddo BHF reaffirms its 'outperform' rating on Genfit and raises its target price from 8.8 to 9.3 euros, despite good Phase III trial results unveiled the previous day by Cymabay, Ipsen/Genfit's main competitor in primary biliary cholangitis.

There are real differences, particularly in terms of pruritus, but the primary endpoint of reduced ALP (alkaline phosphatase) is, after reprocessing, very good for French companies", he points out.

In terms of time to market, elafibranor is therefore mechanically a few months ahead of schedule", continues the analyst, who does not alter his market assumptions, with a launch of this product in 2024 and peak sales of 411 million euros in 2030.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.